Endoscopic Ultrasound Compared With Pancreatic Function Testing for Diagnosis of Chronic Pancreatitis - Full Text View

Sponsors and Collaborators:	The Cleveland Clinic ChiRhoClin, Inc. The National Pancreas Foundation
Information provided by:	The Cleveland Clinic
ClinicalTrials.gov Identifier:	NCT00651053

Purpose

This is a investigator-initiated, single-center, prospective study to evaluate endoscopic ultrasound (EUS) as a diagnostic test for chronic pancreatitis (CP). EUS detects abnormalities of the pancreas that may represent scarring from CP. The validation of any new test requires a comparison with the best available reference standards. There is no true "gold standard" for diagnosis of CP; however, pancreatic function testing (PFT) is highly sensitive for exocrine dysfunction as a surrogate for early fibrosis, and is widely considered the non-histologic gold standard. There are no well-designed prospective studies comparing EUS with PFT as reference standard.

EUS detects parenchymal and ductal features of CP said to correlate with fibrosis. We hypothesize that a predominance of parenchymal fibrosis results in diminished acinar-cell secretion of enzymes. Conversely, a predominance of ductal fibrosis results in impairment of ductal secretion of bicarbonate. Because secretin and cholecystokinin (CCK) PFTs measure unique aspects of pancreatic function (duct-cell and acinar-cell function, respectively), the use of both hormonal stimulants will allow the most comprehensive investigation of the significance of EUS features. There are no studies comparing EUS with combined or dual performance of secretin and CCK PFTs.

The primary objective of this study is to determine the test characteristics of EUS for diagnosis of CP compared with dual secretin- and CCK- stimulated PFTs as reference standard. Secondary objectives include to: 1.

Determine the optimal number and relative functional importance of specific EUS criteria, 2. Compare the test characteristics of linear- and radial-array EUS.

190 patients evaluated for pancreatitis or pancreatic-type abdominal pain will undergo the "new test" (radial and linear EUS) and the reference standard (CCK and secretin PFTs). The EUS examinations will be videotaped and interpreted in a blinded fashion. EUS scores will be compared with PFT results to allow the calculation of sensitivity and specificity of linear and radial EUS. Reciever operating characteristics (ROC) analysis will be used to determine the optimal number of EUS criteria for diagnosis.

Condition	Intervention
Chronic Pancreatitis	Procedure: EUS

Study Type:	Interventional
Study Design:	Diagnostic, Open Label, Uncontrolled, Crossover Assignment
Official Title:	Validation of Endoscopic Ultrasound Criteria for Diagnosis of Chronic Pancreatitis Using Dual Secretin and Cholecystokinin Pancreatic Function Testing as Reference Standard

Resource links provided by NLM:

MedlinePlus related topics: Endoscopy Ultrasound

U.S. FDA Resources

Further study details as provided by The Cleveland Clinic:

Primary Outcome Measures:

Sensitivity and specificity of EUS

Enrollment:	70
Study Start Date:	May 2005
Study Completion Date:	December 2007

Intervention Details:

Sensitivity and specificity of EUS will be compared with PFT as reference standard.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Male or female, age greater than 18 years.
Capable of informed consent.
If female and not more than 1 year post-menopausal, or surgically sterile, must use medically accepted form of contraception or abstain from sexual activities during study.
EUS and CCK ePFT planned for a structural evaluation of the pancreas in patients with pancreatitis or pancreatic-type abdominal pain.

Exclusion Criteria:

Severe cardiac disease (stable or unstable angina, congestive heart failure, uncontrolled arrhythmias, implantable defibrillator, severe valvular disease, etc.).
Severe pulmonary disease (Severe asthma, COPD or interstitial lung disease requiring nebulizer treatment or home oxygen, pulmonary hypertension).
Severe renal disease (history of chronic renal insufficiency [creatinine >2.0] or chronic hemodialysis).
Inability to undergo conscious sedation or general anesthesia.
Ongoing illicit drug use or abuse. Must be drug free for >1 year.
Acute pancreatitis within the past 2 months.
Prior pancreatic surgery.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00651053

Locations

United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195

Sponsors and Collaborators

The Cleveland Clinic

ChiRhoClin, Inc.

The National Pancreas Foundation

More Information

No publications provided

Responsible Party:	Cleveland Clinic Foundatino ( Tyler Stevens, M.D. )
Study ID Numbers:	CRC 2005-01
Study First Received:	March 30, 2008
Last Updated:	March 30, 2008
ClinicalTrials.gov Identifier:	NCT00651053 History of Changes
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Secretin
Digestive System Diseases
Cholecystokinin

Pancreatic Diseases
Pancreatitis
Pancreatitis, Chronic

Additional relevant MeSH terms:

Digestive System Diseases
Pancreatic Diseases
Pancreatitis
Pancreatitis, Chronic

ClinicalTrials.gov processed this record on September 11, 2009